These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30337619)

  • 21. Serum α-1 Antitrypsin (AAT) antagonizes intrinsic apoptosis induction in neutrophils from patients with systemic inflammatory response syndrome.
    Sarabhai T; Peter C; Bär AK; Windolf J; Relja B; Wesselborg S; Wahlers T; Paunel-Görgülü A
    PLoS One; 2017; 12(5):e0177450. PubMed ID: 28493974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α
    Murphy MP; McEnery T; McQuillan K; McElvaney OF; McElvaney OJ; Landers S; Coleman O; Bussayajirapong A; Hawkins P; Henry M; Meleady P; Reeves EP; McElvaney NG
    Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 32060059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro.
    Janciauskiene S; Zelvyte I; Jansson L; Stevens T
    Biochem Biophys Res Commun; 2004 Mar; 315(2):288-96. PubMed ID: 14766206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A.
    Scapini P; Morini M; Tecchio C; Minghelli S; Di Carlo E; Tanghetti E; Albini A; Lowell C; Berton G; Noonan DM; Cassatella MA
    J Immunol; 2004 Apr; 172(8):5034-40. PubMed ID: 15067085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased outer arm and core fucose residues on the N-glycans of mutated alpha-1 antitrypsin protein from alpha-1 antitrypsin deficient individuals.
    McCarthy C; Saldova R; O'Brien ME; Bergin DA; Carroll TP; Keenan J; Meleady P; Henry M; Clynes M; Rudd PM; Reeves EP; McElvaney NG
    J Proteome Res; 2014 Feb; 13(2):596-605. PubMed ID: 24328305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases.
    Mócsai A; Jakus Z; Vántus T; Berton G; Lowell CA; Ligeti E
    J Immunol; 2000 Apr; 164(8):4321-31. PubMed ID: 10754332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency.
    Campbell EJ; Campbell MA; Boukedes SS; Owen CA
    J Clin Invest; 1999 Aug; 104(3):337-44. PubMed ID: 10430615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation therapy for alpha(1)-antitrypsin deficiency.
    Juvelekian GS; Stoller JK
    Drugs; 2004; 64(16):1743-56. PubMed ID: 15301559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha-1 Antitrypsin Therapy Modifies Neutrophil Adhesion in Patients with Obstructive Lung Disease.
    McEnery T; White MM; Gogoi D; Coleman O; Bergin D; Jundi B; Flannery R; Alsaif FAT; Landers SA; Casey M; Dunlea D; Meleady P; McElvaney NG; Reeves EP
    Am J Respir Cell Mol Biol; 2022 Jul; 67(1):76-88. PubMed ID: 35507773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-1-antitrypsin is produced by human neutrophil granulocytes and their precursors and liberated during granule exocytosis.
    Clemmensen SN; Jacobsen LC; Rørvig S; Askaa B; Christenson K; Iversen M; Jørgensen MH; Larsen MT; van Deurs B; Ostergaard O; Heegaard NH; Cowland JB; Borregaard N
    Eur J Haematol; 2011 Jun; 86(6):517-30. PubMed ID: 21477074
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB.
    Hassan T; de Santi C; Mooney C; McElvaney NG; Greene CM
    Sci Rep; 2017 Oct; 7(1):13803. PubMed ID: 29062067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients.
    Turner AM; Stolk J; Bals R; Lickliter JD; Hamilton J; Christianson DR; Given BD; Burdon JG; Loomba R; Stoller JK; Teckman JH
    J Hepatol; 2018 Aug; 69(2):378-384. PubMed ID: 29572094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex-specific differences in emphysema using a murine antisense oligonucleotide model of α-1 antitrypsin deficiency.
    Joshi R; Ojha M; Lewis J; Fan Q; Monia B; Guo S; Varisco BM
    Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1165-L1173. PubMed ID: 31017014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Historical role of alpha-1-antitrypsin deficiency in respiratory and hepatic complications.
    Zuo L; Pannell BK; Zhou T; Chuang CC
    Gene; 2016 Sep; 589(2):118-22. PubMed ID: 26768576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.
    McElvaney NG
    Ann Am Thorac Soc; 2016 Apr; 13 Suppl 2():S191-6. PubMed ID: 27115956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type 1 diabetes contributes to combined pulmonary fibrosis and emphysema in male alpha 1 antitrypsin deficient mice.
    Park SS; Mai M; Ploszaj M; Cai H; McGarvey L; Mueller C; Garcia-Arcos I; Geraghty P
    PLoS One; 2023; 18(10):e0291948. PubMed ID: 37819895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyk2 is required for neutrophil degranulation and host defense responses to bacterial infection.
    Kamen LA; Schlessinger J; Lowell CA
    J Immunol; 2011 Feb; 186(3):1656-65. PubMed ID: 21187437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency.
    Borel F; Tang Q; Gernoux G; Greer C; Wang Z; Barzel A; Kay MA; Shultz LD; Greiner DL; Flotte TR; Brehm MA; Mueller C
    Mol Ther; 2017 Nov; 25(11):2477-2489. PubMed ID: 29032169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.
    O'Brien ME; Murray G; Gogoi D; Yusuf A; McCarthy C; Wormald MR; Casey M; Gabillard-Lefort C; McElvaney NG; Reeves EP
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency.
    Karadagi A; Cavedon AG; Zemack H; Nowak G; Eybye ME; Zhu X; Guadagnin E; White RA; Rice LM; Frassetto AL; Strom S; Jorns C; Martini PGV; Ellis E
    Sci Rep; 2020 Apr; 10(1):7052. PubMed ID: 32341402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.